DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.
In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he...
Fluo Labs, Inc. is a premarket clinical stage medical device company pursuing innovative technology to provide drug-free relief of nasal allergy (i.e. hay fever)...
